8-K: Kyverna Therapeutics Presents Positive CAR T Data

Kyverna Therapeutics announced positive longer-term follow-up data from its Phase 2 trial of miv-cel in generalized myasthenia gravis and primary analysis results from its registrational trial in stiff person syndrome.

Summary

• Kyverna Therapeutics presented updated clinical data for its lead drug candidate, miv-cel (mivocabtagene autoleucel), a fully human autologous CD19 CAR T therapy.
• Positive results were announced from the Phase 2 portion of the KYSA-6 trial in generalized myasthenia gravis (gMG), showing sustained clinical benefit and reduced treatment burden.
• Additionally, primary analysis results from the KYSA-8 registrational trial in stiff person syndrome (SPS) demonstrated significant improvements in mobility and a durable, drug-free remission.
• The company is preparing for a Biologics License Application (BLA) submission for miv-cel in SPS and is advancing its Phase 3 trial in gMG.
• Miv-cel is designed for potency and tolerability, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed in the presented data.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong efficacy and safety data presented for miv-cel in two significant autoimmune indications, positioning the company for potential regulatory approval and market leadership.

Positives

• Miv-cel demonstrated statistically significant and durable clinical benefit across all endpoints in the KYSA-8 SPS trial, with 100% of patients achieving clinically meaningful response in T25FW and remaining free of immunotherapies.
• In the KYSA-6 gMG trial, 100% of patients achieved clinically meaningful response in MG-ADL and QMG scores, with 57% reaching minimal symptom expression (MSE) at last follow-up.
• Miv-cel showed a well-tolerated safety profile in both trials, with no high-grade CRS or ICANS observed.
• The drug candidate achieved deep B-cell depletion and markers of broad immune reset, supporting durable remission.
• Kyverna Therapeutics is advancing towards a BLA submission for miv-cel in SPS, a condition with no currently approved therapies.
• The Phase 3 trial for gMG is progressing with first patients enrolled and sites activated globally.

Negatives

• Four patients in the SPS trial experienced Grade 3/4 neutropenia, an expected adverse event with lymphodepletion and CAR T-cell therapies, though manageable.
• In the gMG trial, two patients experienced Grade 3/4 neutropenia, which was manageable and not associated with infections.
• While generally well-tolerated, CRS was observed in 92% of SPS patients and 100% of gMG patients, though primarily low-grade.
• The data for gMG is from a small Phase 2 cohort (n=7), and the Phase 3 trial is ongoing.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those described in the company's SEC filings, which could cause actual results to differ materially.
• The use of miv-cel in named-patient access programs is not a substitute for clinical trials and results may not be used for regulatory approval.
• The company has not independently verified the accuracy or completeness of third-party estimates regarding market size.
• The success of miv-cel is dependent on regulatory approvals, which are not guaranteed.
• Competition exists in the treatment of autoimmune diseases, and other therapies may offer comparable or superior outcomes.

Future Outlook

The company is preparing for a BLA submission for miv-cel in SPS and is advancing its Phase 3 trial in gMG, indicating a strong focus on regulatory approval and market entry for its lead candidate.

Management Comments

• Miv-cel has the potential to be the first approved autoimmune CAR T therapy, offering drug-free, disease-free remission with a single dose.
• The company is positioned to deliver the first approved autoimmune CAR T, with lead indications in SPS and gMG addressing significant unmet medical needs.
• New data reinforce Kyverna's differentiated neuroimmunology franchise opportunity, further supporting the path to approval and confidence in launch.
• Miv-cel is designed for potency and tolerability, with over 100 patients dosed across multiple indications.

Industry Context

StockSavvy.ai notes that Kyverna Therapeutics is at the forefront of developing CAR T therapies for autoimmune diseases, a rapidly evolving field. The positive data presented for miv-cel in both SPS and gMG, if successful in regulatory review, could establish Kyverna as a leader in this niche, potentially disrupting existing treatment paradigms that often rely on chronic immunosuppression.

Comparison to Industry Standards

• In the SPS trial, 81% of patients achieved a clinically meaningful improvement (20% reduction) in the T25FW, with 31% completing the test in <5 seconds, a typical time for healthy adults.
• For gMG, 100% of patients achieved a clinically meaningful response (3-point reduction) in MG-ADL and QMG scores, with 57% reaching minimal symptom expression (MSE) at last follow-up.
• Compared to other investigational therapies for gMG, miv-cel demonstrated a higher percentage of patients achieving minimal symptom expression (57% vs. up to 43% for other therapies) and a greater mean reduction in MG-ADL and QMG scores.
• Miv-cel's profile of achieving durable, drug-free remission without high-grade CRS or ICANS differentiates it from many existing and emerging autoimmune therapies.

Stakeholder Impact

• Shareholders: Positive data may lead to increased confidence and potential stock price appreciation.
• Patients with SPS: Potential for the first approved therapy offering durable, drug-free remission.
• Patients with gMG: Continued progress in developing a potentially transformative treatment option.
• Healthcare Providers: New therapeutic option with a favorable safety profile for treating severe autoimmune conditions.

Next Steps

• Prepare for Biologics License Application (BLA) submission for miv-cel in SPS.
• Continue enrollment and conduct the Phase 3 trial for miv-cel in gMG.
• Host a conference call to review the announced results.

Key Dates

Recommendation

The presented data for miv-cel in both SPS and gMG are highly compelling, demonstrating significant efficacy and a favorable safety profile, particularly the absence of high-grade CRS/ICANS. The potential for first-in-class approval in SPS and strong Phase 2 results in gMG, coupled with a clear regulatory path and commercial strategy, suggests substantial upside potential for investors.

Keywords

Kyverna Therapeutics, miv-cel, CAR T, Stiff Person Syndrome, Generalized Myasthenia Gravis, KYSA-8, KYSA-6, Neuroimmunology